AOD 9604, MOTS-c, and tesamorelin compared: how each research peptide works, typical dosing protocols, and what human data actually show in studies.
Short answer: AOD 9604, MOTS-c, and tesamorelin are three different peptides studied for fat metabolism and metabolic health, but they are not interchangeable. Tesamorelin is the only one with FDA approval for any human use, and that approval covers a narrow patient group. AOD 9604 and MOTS-c remain research compounds with no approved human indication.
What Each Peptide Actually Is
AOD 9604 is a modified fragment of human growth hormone made from the last 16 amino acids of the hGH molecule, known as residues 176-191. Scientists designed it to keep the fat-metabolizing portion of growth hormone while avoiding its effects on blood glucose and IGF-1.
MOTS-c is a mitochondrial-derived peptide, a 16-amino-acid sequence encoded inside mitochondrial DNA rather than the cell nucleus. It has no structural relationship to growth hormone and appears to act mainly on cellular energy sensing and insulin sensitivity.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It signals the pituitary to release the body's own growth hormone, which then increases lipolysis and reduces visceral fat.
AOD 9604 vs MOTS-c vs Tesamorelin at a Glance
| Feature | AOD 9604 | MOTS-c | Tesamorelin |
|---|---|---|---|
| Class | hGH fragment (176-191) | Mitochondrial-derived peptide | GHRH analog |
| Primary action | Stimulates lipolysis in fat cells | Regulates mitochondrial metabolism and insulin sensitivity | Raises endogenous GH, reduces visceral fat |
| FDA status | Not approved for human use | Not approved for human use | Approved for HIV-associated lipodystrophy |
| Human data | Trials ran, weight-loss endpoints failed | Observational data only | Randomized trials show visceral fat reduction |
| Route | Subcutaneous (research use) | Subcutaneous (research use) | Subcutaneous injection, prescription |
AOD 9604 vs Tesamorelin: The Evidence Gap
In a direct aod 9604 vs tesamorelin comparison, the difference in clinical evidence is enormous. Tesamorelin has randomized, placebo-controlled trials showing roughly 15-18% reductions in visceral adipose tissue in adults with HIV-associated lipodystrophy.
AOD 9604 also reached human trials, and those trials failed to produce clinically meaningful weight loss compared with placebo. That outcome is the main reason the compound never received approval.
The aod 9604 vs mots-c question is harder still, because the two peptides do not act on the same system at all. AOD 9604 targets fat cell metabolism directly, while MOTS-c works on mitochondrial energy signaling and glucose handling.
Does Stacking AOD-9604 and MOTS-c Make Sense?
People who research aod-9604 and mots-c together usually want to pair a lipolytic signal with a metabolic one. The theory is that one peptide mobilizes stored fat while the other improves how muscle tissue uses energy.
That reasoning is still theoretical. Research forums frequently debate an aod-9604 mots-c tesamorelin stack, yet no published human trial has tested all three compounds together, and each one carries a different regulatory status.
Dosing: What Is Actually Known
Search interest in aod 9604 mots-c tesamorelin dosage is high, but only tesamorelin has an established human dose. The FDA-approved regimen is a once-daily subcutaneous injection of 2 mg, or 1.4 mg with the newer formulation.
- Tesamorelin: an approved daily dose exists, and it requires a prescription.
- AOD 9604: no validated human dose; community protocols cite 250-500 mcg per day based on anecdotal reports rather than controlled trials.
- MOTS-c: no validated human dose; community protocols cite roughly 5-10 mg per week, which is also unverified.
No clinical study has established a safe or effective dose of AOD 9604 or MOTS-c for humans. Any number circulating online should be treated as an unproven claim, not a protocol.
Safety, Sourcing, and Legal Status
Peptides sold as "research chemicals" bypass the FDA drug approval pathway, so purity, sterility, and actual content are not guaranteed. Buyers frequently receive underdosed or mislabeled vials, and contaminated injectables carry real risks of infection and immune reactions.
Tesamorelin is different because it is a prescription product with a regulated supply chain. Its label still carries warnings about elevated IGF-1, injection site reactions, joint pain, and fluid retention, and it is not intended for general weight loss.
Anyone considering these compounds should consult a licensed healthcare professional. Self-directed use of unapproved peptides is a decision with more unknowns than answers.
Key Takeaways
- Tesamorelin is the only one of these three peptides with FDA approval for human use, and that approval is limited to reducing visceral fat in adults with HIV-associated lipodystrophy.
- AOD 9604 is not FDA-approved for human use, and its human trials did not show meaningful weight loss.
- MOTS-c remains an investigational mitochondrial peptide with no approved human use and no randomized human dosing trials.
- None of these peptides is approved for general weight loss in the United States.
- The three compounds act through different pathways, so stacking them does not create a single predictable effect.
Frequently Asked Questions
Is AOD 9604 or MOTS-c FDA approved for weight loss?
No. Neither AOD 9604 nor MOTS-c is FDA-approved for weight loss or any other human use in the United States. Tesamorelin is the only peptide of the three with approval, and it is indicated specifically for visceral fat reduction in adults with HIV-associated lipodystrophy, not for general weight loss.
What is the difference between tesamorelin and AOD 9604?
Tesamorelin is a GHRH analog that raises your own growth hormone levels and has approved human trials showing visceral fat reduction. AOD 9604 is a fragment of growth hormone that was tested in humans but failed to produce meaningful weight loss compared with placebo, and it has no FDA approval.
Can you stack AOD 9604, MOTS-c, and tesamorelin together?
No published human trial has tested these three peptides in combination, so there is no evidence on safety or effectiveness for a stack. Each compound works through a different pathway, and two of the three are unapproved research chemicals with no established human dose.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.